Page 385 - Read Online
P. 385

Page 14 of 16                    Verkoeijen et al. J Cancer Metastasis Treat 2019;5:51  I  http://dx.doi.org/10.20517/2394-4722.2019.06


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2019.



               REFERENCES
               1.   Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
               2.   Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18.
               3.   Fidler IJ, Kripke ML. The challenge of targeting metastasis. Cancer Metastasis Rev 2015;34:635-41.
               4.   Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 2018;18:533-48.
               5.   Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
               6.   Sethi  N, Kang Y. Unravelling  the complexity  of metastasis  - molecular  understanding and targeted therapies.  Nat  Rev  Cancer
                   2011;11:735-48.
               7.   Huang C, Jacobson K, Schaller MD. A role for JNK-paxillin signaling in cell migration. Cell Cycle 2004;3:4-6.
               8.   Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117:4619-28.
               9.   Huang  Z,  Yan  DP,  Ge  BX.  JNK  regulates  cell  migration  through  promotion  of  tyrosine  phosphorylation  of  paxillin.  Cell  Signal
                   2008;20:2002-12.
               10.   Le Devedec SE, van Roosmalen W, Maria N, Grimbergen M, Pont C, et al. An improved model to study tumor cell autonomous
                   metastasis programs using MTLn3 cells and the Rag2(-/-) gammac (-/-) mouse. Clin Exp Metastasis 2009;26:673-84.
               11.   Omran  OM,  Al  SM.  Cytoskeletal  focal  adhesion  proteins  fascin-1  and  paxillin  are  predictors  of  malignant  progression  and  poor
                   prognosis in human breast cancer. J Environ Pathol Toxicol Oncol 2015;34:201-12.
               12.   Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
               13.   Chen J, Gallo KA. MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive
                   metastasis. Cancer Res 2012;72:4130-40.
               14.   Shin EY, Kim SY, Kim EG. c-Jun N-terminal kinase is involved in motility of endothelial cell. Exp Mol Med 2001;33:276-83.
               15.   Xia Y, Makris C, Su B, Li E, Yang J, et al. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory
                   stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A. 2000;97:5243-8.
               16.   Kavurma MM, Khachigian LM. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically
                   distinct smooth muscle cell subtypes. J Cell Biochem 2003;89:289-300.
               17.   Kawauchi T, Chihama K, Nabeshima Y, Hoshino M. The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration.
                   EMBO J 2003;22:4190-201.
               18.   Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, et al. A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement
                   and embryonic eyelid closure. EMBO J. 2003;22:4443-54.
               19.   Berginski ME, Vitriol EA, Hahn KM, Gomez SM. High-resolution quantification of focal adhesion spatiotemporal dynamics in living
                   cells. PLoS One 2011;6:e22025.
               20.   Guo L, Guo Y, Xiao S, Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in
                   hepatocellular carcinoma. Life Sci 2005;77:1869-78.
               21.   Yin Y, Wang S, Sun Y, Matt Y, Colburn NH, et al. JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of
                   vascular endothelial growth factor in MCF7 cells. Biomed Pharmacother 2009;63:429-35.
               22.   Kappelmann M, Bosserhoff A, Kuphal S. AP-1/c-Jun transcription factors: regulation and function in malignant melanoma. Eur J Cell
                   Biol 2014;93:76-81.
               23.   Lee MH, Koria P, Qu J, Andreadis ST. JNK phosphorylates beta-catenin and regulates adherens junctions. FASEB J 2009;23:3874-83.
               24.   Huang  C,  Rajfur  Z,  Borchers  C,  Schaller  MD,  Jacobson  K.  JNK  phosphorylates  paxillin  and  regulates  cell  migration.  Nature
                   2003;424:219-23.
               25.   Miyamoto Y, Torii T, Yamamori N, Eguchi T, Nagao M, et al. Paxillin is the target of c-Jun N-terminal kinase in Schwann cells and
                   regulates migration. Cell Signal 2012;24:2061-9.
               26.   Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol 2000;2:E231-6.
               27.   Turner CE. Paxillin interactions. J Cell Sci 2000;113 Pt 23:4139-40.
               28.   Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18:516-23.
               29.   Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol 2007;9:858-67.
               30.   Huveneers S, Danen EH. Adhesion signal. J Cell Sci 2009;122:1059-69.
               31.   Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009;122:159-63.
   380   381   382   383   384   385   386   387   388   389   390